{"id":"63fa66ee-3540-5641-a3db-ef6b482f3102","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-transporter-slc22a6","predicate":"decreases_in_recorded_comparison","statement":"RA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"0301cad4-bbed-502c-9872-4d108c9245a0","mechanism_event_label":"RA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"4872be13-147b-53b0-bd51-c717906aa430","slug":"slc22a6","display_name":"Human organic anion transporter 1 / SLC22A6","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"0301cad4-bbed-502c-9872-4d108c9245a0","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-transporter-slc22a6-event","event_type":"experimental_observation","label":"RA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.","description":"### ra-transporter-slc22a6\n\nRA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.\nInhibition does not demonstrate that RA is transported by this protein.\nModel and exposure: Engineered HEK293 transporter versus mock cells; five-minute uptake.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA concentration series","sequence_order":0,"notes":""},{"entity":{"id":"4872be13-147b-53b0-bd51-c717906aa430","slug":"slc22a6","display_name":"Human organic anion transporter 1 / SLC22A6","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA concentration series\", \"comparator\": \"Probe uptake without RA\", \"endpoint\": \"RA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Engineered HEK293 transporter versus mock cells; five-minute uptake.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-transporter-slc22a6; Inhibition does not demonstrate that RA is transported by this protein.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f5a7d531-e12f-541b-ac76-4fc4c4e2575f","evidence_kind":"source_excerpt","locator":"Lines 373-379","start_line":373,"end_line":379,"excerpt":"### ra-transporter-slc22a6\n\nRA inhibited human SLC22A6 probe-substrate transport, IC50 60.6 micromolar.\nInhibition does not demonstrate that RA is transported by this protein.\nModel and exposure: Engineered HEK293 transporter versus mock cells; five-minute uptake.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Engineered HEK293 transporter versus mock cells; five-minute uptake.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}